2019; Adult; Alendronate; Angiotensin receptor antagonists; Angiotensin-converting enzyme inhibitors; BMI; Beta-blockers; Bisoprolol*; Bisphosphonates; Blood pressure; Brain natriuretic peptide; CD-56; CDX2*; CT scan; Calcium; Cardiomyopathy; Cardiomyopathy*; Chromogranin B*; Echocardiogram; Electrocardiogram; Endocrine-related cancer; Fatigue; Female; Furosemide; Gliclazide; Glucagon; Glucagonoma; Heart; Heart failure; Hepatic metastases; Hyperglucagonaemia; Hyperglucogonaemia; Hypotension; Lanreotide; Left ventricular ejection fraction*; Left ventricular internal diameter*; Losartan; MRI; March; Necrolytic migratory erythema; Neuroendocrine tumour; Octreotide scan; Oedema; Oncology; PAX8*; Palpitations; Pancreas; Ramipril; Rash; Somatostatin analogues; Spironolactone; Sulphonylureas; Synaptophysin; Tachycardia; Ultrasound-guided biopsy; Unique/unexpected symptoms or presentations of a disease; United Kingdom; Vitamin D; Weight loss; White